Trial · NCT02506959

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

NCT02506959, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2025-03-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma. Trials, record NCT02506959. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02506959

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
NCT number: NCT02506959
Status: Completed
Phases: Phase 2
Enrollment: 83 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
First posted: 2015-07-23
Last updated: 2025-03-18
Results first posted: 2025-03-18

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival (PFS)	1 year	Number of participants alive and disease free one year post auto transplant in patients with refractory or relapsed myeloma receiving panobinostat/gemcitabine/busulfan/melphalan (panobinostat/Gem/Bu/Mel) with autologous stem-cell transplant, either as a first or a salvage stem-cell transplant.
Secondary	Overall Survival (OS)	Up to 2 years	Number of participants with refractory or relapse Myeloma who still remain alive two years post transplant
Secondary	Participants Who Experienced Grade 3 or Higher Adverse Events	Up to day 100	Number of Participants who experienced grade 3 or higher Adverse Events during the first 100 days of the transplant.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Progression Free Survival (PFS)	1 year	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall Survival (OS)	Up to 2 years	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Participants Who Experienced Grade 3 or Higher Adverse Events	Up to day 100	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Progression Free Survival (PFS)	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	38	Participants
Progression Free Survival (PFS)	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	24	Participants
Overall Survival (OS)	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	27	Participants
Overall Survival (OS)	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	16	Participants
Participants Who Experienced Grade 3 or Higher Adverse Events	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	47	Participants
Participants Who Experienced Grade 3 or Higher Adverse Events	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	29	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	50
Overall Study	STARTED	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	33
Overall Study	COMPLETED	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	48
Overall Study	COMPLETED	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	32
Overall Study	NOT COMPLETED	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	2
Overall Study	NOT COMPLETED	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	1

Source ClinicalTrials.gov

Adverse events114

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal pain	Gastrointestinal disorders	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	1	50	1
other	Abdominal pain	Gastrointestinal disorders	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	2	33	2
other	ALK increased	Investigations	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	2	50	2
other	ALK increased	Investigations	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	3	33	3
other	Allergic reaction	Immune system disorders	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	1	50	1
other	Allergic reaction	Immune system disorders	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	1	33	1
other	ALT increased	Investigations	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	25	50	25
other	ALT increased	Investigations	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	20	33	20
other	Anorexia	Metabolism and nutrition disorders	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	0	50	0
other	Anorexia	Metabolism and nutrition disorders	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	1	33	1

1 to 10 of 114Source ClinicalTrials.gov

See all 114 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	23	50
Total, all-cause mortality	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	17	33
Total, other adverse events	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	47	50
Total, other adverse events	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	30	33
Total, serious adverse events	Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	2	50
Total, serious adverse events	Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel	4	33

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA016672	The University of Texas MD Anderson Cancer Center Support Grant (CCSG)	KOONG, ALBERT	UNIVERSITY OF TX MD ANDERSON CAN CTR	NATIONAL CANCER INSTITUTE	1985 to 2026

Source NIH RePORTER

Trial comparisons5

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel vs Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel: Participants Who Experienced Grade 3 or Higher Adverse Events	Trial comparisons
Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel vs Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel: Overall Survival (OS)	Trial comparisons
Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel vs Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel: Progression Free Survival (PFS)	Trial comparisons
Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel vs Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel: deaths from any cause	Trial comparisons
Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel vs Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02506959

GET https://conductscience.org/api/trials/v1/NCT02506959/events?page=2

API reference For AI assistants